Last reviewed · How we verify
Vatalinib
Vatalinib is a Small molecule drug developed by Novartis. It is currently in Phase 1 development.
Vatalanib is a small molecule inhibitor of the stem cell growth factor receptor Kit. It has been studied in clinical trials for various conditions, including wet age-related macular degeneration, colorectal neoplasms, and kidney cancer.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Novartis is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vatalinib |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (PHASE1)
- Trial of PTK787/ZK 222584 Plus Paclitaxel (PHASE1)
- PTK/ZK in Disseminated Malignant Melanoma (PHASE1, PHASE2)
- Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors (PHASE1)
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. (PHASE3)
- Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors (PHASE1)
- Vatalanib in Treating Patients With Recurrent or Progressive Meningioma (PHASE2)
- Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vatalinib CI brief — competitive landscape report
- Vatalinib updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Vatalinib
What is Vatalinib?
Who makes Vatalinib?
What development phase is Vatalinib in?
Related
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing